Skip to content

FGF-21 and Exercise in Relation to Insulin Secretion

FGF-21 During Physical Exercise in Patients With Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus and Healthy Controls

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02667964
Enrollment
60
Registered
2016-01-29
Start date
2015-11-30
Completion date
2017-06-30
Last updated
2016-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical Activity

Brief summary

FGF-21 and insulin are key hormones in the regulation of glucose metabolism. Furthermore, both hormones are influenced by physical activity. The following hypothesis will be tested: FGF-21 is regulated insulin-dependent during exercise.

Detailed description

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by rising global importance. In Germany alone, more than seven million people are being treated currently. T2DM is characterized by permanently elevated blood glucose levels, based on insulin resistance and followed by associated beta cell failure. In our previous work the investigators could already shown that increased FGF-21 levels are accompanied by an increased risk of T2DM. Physical activity is essential in the treatment and the prevention of T2DM. Interestingly, it was shown that acute physical exercise was leading to decreased insulin levels and increased FGF-21 values. In this study the effects of acute physical activity on FGF-21 values should be investigated in 3 groups: a) Healthy volunteers b) persons with T2DM c) persons with T1DM.

Interventions

Spiroergometry on a bicycle ergometer

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers,persons with T2DM, persons with T1DM

Exclusion criteria

* Patients with contraindications to an exercise ECG or spirometry be excluded from participation in the study.

Design outcomes

Primary

MeasureTime frame
FGF-21 change after physical activityFGF-21 before and 1 h after spiroergometry

Countries

Germany

Contacts

Primary ContactThomas Bobbert, Dr.
thomas.bobbert@charite.de450514252

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026